4//SEC Filing
Pierce Valerie L 4
Accession 0001209191-23-054735
CIK 0001426332other
Filed
Nov 7, 7:00 PM ET
Accepted
Nov 8, 6:12 PM ET
Size
17.2 KB
Accession
0001209191-23-054735
Insider Transaction Report
Form 4
Pierce Valerie L
SVP, GC & CCO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−200,000→ 0 totalExercise: $13.42Exp: 2029-09-30→ Common Stock (200,000 underlying) - Award
Stock Option (Right to Buy)
2023-11-06+200,000→ 200,000 totalExercise: $0.84Exp: 2029-09-30→ Common Stock (200,000 underlying) - Award
Stock Option (Right to Buy)
2023-11-06+100,000→ 100,000 totalExercise: $0.84Exp: 2031-03-16→ Common Stock (100,000 underlying) - Award
Stock Option (Right to Buy)
2023-11-06+150,000→ 150,000 totalExercise: $0.84Exp: 2032-03-02→ Common Stock (150,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−100,000→ 0 totalExercise: $31.93Exp: 2031-03-16→ Common Stock (100,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-11-06−150,000→ 0 totalExercise: $15.20Exp: 2032-03-02→ Common Stock (150,000 underlying)
Footnotes (4)
- [F1]Fully vested.
- [F2]Effective November 6, 2023, the Compensation Committee of the Board of Directors of NGM Biopharmaceuticals, Inc. (the "Company") approved a stock option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of a previously-granted stock option in exchange for a new stock option having a lower exercise price of $0.84 per share, which is the closing price of the Company's common stock on November 6, 2023. The reduced exercise price is subject to the relevant retention period and other terms outlined in the applicable stock option repricing notice. All of the other terms of the stock option remained unchanged.
- [F3]The shares subject to the stock option vest over a four-year period commencing January 1, 2021, with 1/48th of the shares vesting on a monthly basis.
- [F4]The shares subject to the stock option vest over a four-year period commencing January 1, 2022, with 1/48th of the shares vesting on a monthly basis.
Documents
Issuer
NGM BIOPHARMACEUTICALS INC
CIK 0001426332
Entity typeother
Related Parties
1- filerCIK 0001397112
Filing Metadata
- Form type
- 4
- Filed
- Nov 7, 7:00 PM ET
- Accepted
- Nov 8, 6:12 PM ET
- Size
- 17.2 KB